FDA approves Alexion’s Soliris to treat adults with neuromyelitis optica spectrum disorder

This article was originally published here

The NMOSD is a rare and severe autoimmune disease, which attacks the central nervous system without warning. Also referred as relapses, the attacks may result in progressive and

The post FDA approves Alexion’s Soliris to treat adults with neuromyelitis optica spectrum disorder appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply